SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

Repeated insider purchases, including buying by CEO Ryan Cohen and director Nat Turner, are driving attention and fueling traders hopes for a breakout or short squeeze. Others argue the purchases have not led to sustained gains and say GameStop needs concrete business news, while debate also centers on options and upcoming warrant expiry.

Vistra Corp. is a holding company, which engages in the provision of electricity and power generation. It operates through the following segments: Retail, Texas, East, West, and Asset Closure. The Retail segment includes sale of electricity and natural gas to residential, commercial, and industrial customers. The Texas and East segments are involved in electricity generation, wholesale energy sales and purchases, commodity risk management activities, fuel production and fuel logistics management. The West segment represents the company's electricity generation operations in CAISO. The Asset Closure segment refers to the decommissioning and reclamation of retired plants and mines. The company was founded in 1882 and is headquartered in Irving, TX.

Vistra Corp

A reported federal loan package for upgrades and capacity expansion at three Vistra nuclear plants is driving attention, reinforcing the AI and data-center power-demand thesis. Traders are largely optimistic about the potential support but note the financing is a loan and debate whether the news will overcome the stocks choppy price action.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

A sharp, high-volume breakout without a disclosed company announcement has sparked speculation about institutional buying and short covering, while some traders caution that the rally could fade without confirmed news. Bulls cite Anktivas commercial momentum and upcoming regulatory and trial catalysts; claims of leaked news or an imminent squeeze remain unconfirmed.

MaxLinear, Inc. engages in the provision of communications systems-on-chip (SoC) solutions used in broadband, mobile and wireline infrastructure, data center, and industrial and multi-market applications. Its products include cable broadband modems and gateways, wireline connectivity devices, radio frequency transceivers, fiber-optic modules, video set-top boxes and gateways, hybrid analog and digital televisions, direct broadcast satellite outdoor and indoor units, and power management and interface products. The company was founded by Kimihiko Imura, Curtis C. Ling, and Kishore V. Seendripu on September 25, 2003 and is headquartered in Carlsbad, CA.

MaxLinear Inc

MaxLinear shares are surging alongside strength in semiconductors, with traders pointing to the jobs report and broader market momentum rather than a company-specific announcement. The sharp move has drawn momentum buyers, while some warn the stock may be overbought after its recent run.

Western Digital Corp. engages in the development, manufacture, marketing, and sale of data storage devices and solutions. It operates through the Hard Disk Drives (HDD) segment. The company was founded by Alvin B. Phillips in 1970 and is headquartered in San Jose, CA.

Western Digital Corp.

Toshibas reported plan to double HDD capacity for AI data centers has weighed on WDC amid concerns that added competition could weaken pricing power. Many traders call the selloff an overreaction, pointing to the long timeline for Toshibas expansion and continued AI-storage demand, while others see a credible medium-term supply risk.

Seagate Technology Holdings Plc operates as holding company that is engaged in the development, production, and distribution of data storage products and electronic data storage solutions. Its products include hard disk drives, solid state hybrid drives, solid state drives, peripheral component interconnect express cards, serial advanced technology attachment controllers, storage subsystems and computing solutions. The firm offers its products under the Backup Plus and Expansion product lines, and Maxtor and LaCie brands. The company was founded in 1978 and is headquartered in Fremont, CA.

Seagate Technology Holdings Plc

Reports that Toshiba plans to expand HDD capacity for AI data centers have sparked concern that added competition could weaken Seagates pricing power and market share. Many traders view the selloff as an overreaction, arguing that AI-driven demand remains strong and Toshibas capacity ramp is years away, while others see a credible medium-term supply risk.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Cerebras is drawing attention amid concerns about staggered IPO share unlocks and insider selling, alongside reports that OpenAIs latest ultrafast model may be running on Nvidia GPUs rather than Cerebras hardware; the OpenAI claim remains unconfirmed. Bears see potential supply pressure and risk to the customer relationship, while bulls argue that AI-inference demand, existing commitments and new partnerships support the growth case.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivians record Q3 deliveries beat analyst expectations, but shares sold off as the company reaffirmed rather than raised its annual delivery outlook, prompting a sell-the-news reaction. Traders are split between optimism about the R2 ramp and concern that stronger volume still has not resolved questions about profitability and execution.

AGNC Investment Corp. engages in the operation of a real estate investment trust. The firm invests in residential mortgage pass-through securities and collateralized mortgage obligations for which the principal and interest payments are guaranteed by the United States government-sponsored enterprise or by the United States government agency. It also invests in other types of mortgage and mortgage-related securities, such as credit risk transfer securities and non-Agency residential and commercial mortgage-backed securities, where repayment of principal and interest is not guaranteed by the United States government-sponsored enterprise or by the United States Government agency, and other assets related to the housing, mortgage, or real estate markets. The company was founded on January 7, 2008 and is headquartered in Bethesda, MD.

AGNC Investment Corp

AGNC is drawing attention amid a sharp decline tied in traders view to rising Treasury yields and mortgage-backed-securities repricing, which pressure rate-sensitive mortgage REITs. Income-focused holders are buying the dip for its monthly dividend, while others worry about further losses and the dividends sustainability.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovin is drawing attention amid a steep, extended selloff that traders link to analyst concerns about growth and Pixel adoption, alongside the Unity ad-data dispute and the courts denial of AppLovins request for a temporary restraining order. The community is split between viewing the decline as evidence of weakening prospects and seeing it as an oversold move despite strong fundamentals; claims of manipulation remain speculation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Lakewood-Amedex Biotherapeutics Announces Participation in October Conferences

Lakewood-Amedex Biotherapeutics Announces Participation in October Conferences Lakewood-Amedex Biotherapeutics Announces Participation in October ConferencesPR NewswireSARASOTA, Fla., Oct. 1, 2026SARASOTA, Fla., Oct. 1, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics, Inc. (NASDAQ: LABT, the...

LABT’s Nu-3 Takes Aim at Resistant Foot Infections as Phase 2 Catalyst Looms

Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) is heading deeper into the clinical stage with its lead antimicrobial candidate Nu-3, and fresh laboratory data are giving the company another potential catalyst as its Phase 2a trial gets underway.

Lakewood-Amedex Biotherapeutics Announces Positive Data Against Recent Clinical Isolates from Infected Diabetic Foot Ulcers

Lakewood-Amedex Biotherapeutics Announces Positive Data Against Recent Clinical Isolates from Infected Diabetic Foot Ulcers Lakewood-Amedex Biotherapeutics Announces Positive Data Against Recent Clinical Isolates from Infected Diabetic Foot UlcersPR NewswireSARASOTA, Fla., Sept. 28, 2026 Lead...

Lakewood-Amedex Biotherapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of Nu-3 for Infected Diabetic Foot Ulcers

Lakewood-Amedex Biotherapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of Nu-3 for Infected Diabetic Foot Ulcers Lakewood-Amedex Biotherapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of Nu-3 for Infected Diabetic Foot UlcersPR NewswireSARASOTA, Fla., Sept. 24...

Lakewood-Amedex Biotherapeutics CEO Issues Letter to Shareholders Highlighting Transformational Progress and Outlook for Nu-3

Lakewood-Amedex Biotherapeutics CEO Issues Letter to Shareholders Highlighting Transformational Progress and Outlook for Nu-3 Lakewood-Amedex Biotherapeutics CEO Issues Letter to Shareholders Highlighting Transformational Progress and Outlook for Nu-3PR NewswireSARASOTA, Fla., Sept. 21...

Lakewood-Amedex Biotherapeutics Announces IRB Approval and Clinical Site Readiness to Initiate Phase 2a Clinical Trial of Nu-3 for the Treatment of Infected Diabetic Foot Ulcers

Lakewood-Amedex Biotherapeutics Announces IRB Approval and Clinical Site Readiness to Initiate Phase 2a Clinical Trial of Nu-3 for the Treatment of Infected Diabetic Foot Ulcers Lakewood-Amedex Biotherapeutics Announces IRB Approval and Clinical Site Readiness to Initiate Phase 2a Clinical Trial of...

Lakewood-Amedex Biotherapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference

Lakewood-Amedex Biotherapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference Lakewood-Amedex Biotherapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference PR Newswire SARASOTA, Fla., Sept. 8, 2026 SARASOTA, Fla., Sept. 8, 2026 /PRNewswire...

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Gainers

bioAffinity Technologies (NASDAQ:BIAF) shares increased by 68.4% to $7.68 during Tuesday's pre-market session. The market value of their outstanding shares is at $2.7 million.
Lakewood-Amedex (NASDAQ:LABT)read more...

12 Health Care Stocks Moving In Monday's After-Market Session

Gainers

Lakewood-Amedex (NASDAQ:LABT) stock rose 38.0% to $3.45 during Monday's after-market session. The company's market cap stands at $5.4 million.
Alamar Biosciences (NASDAQ:ALMR) stock rose 7.4% to $32.8.read more...

12 Health Care Stocks Moving In Wednesday's Intraday Session

Gainers

Advanced Biomed (NASDAQ:ADVB) shares moved upwards by 108.6% to $14.77 during Wednesday's regular session. The company's market cap stands at $11.5 million.
Lakewood-Amedex (NASDAQ:LABT) shares movedread more...

Lakewood-Amedex Biotherapeutics, Inc. engages in the development of novel antimicrobial therapies. Its anti-infective products targeted certain viral diseases like avian influenza, Epstein Barr Virus (EBV), and hepatitis B and C. The company was founded by Roderic Dale on July 11, 2006 and is headquartered in Bradenton, FL.

Lakewood-Amedex Biotherapeutics Inc.

This Newly Listed Biotech Is Soaring – Retail Says $14 Is The Line In The Sand

Equity

Extremely Bullish Sentiment

Up more than 5%

Flat to up 5%

Flat to down 5%

Down more than 5%

What&#39;s your expected total return for the S&amp;P 500 ($SPY) in Q4? 

Drop your reasoning in the comments.

Stocktwits

What's your expected total return for the S&P 500 (

) in Q4? 

Drop your reasoning in the comments.

Feed

News

Sentiment

Fundamentals

Info

LABT Lakewood-Amedex Biotherapeutics Inc.

Fundamentals

Latest LABT News